See more : urban-gro, Inc. (UGRO) Income Statement Analysis – Financial Results
Complete financial analysis of Embecta Corp. (EMBC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Embecta Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- SW Investments Limited (SW1.BO) Income Statement Analysis – Financial Results
- Tower Resources plc (TRP.L) Income Statement Analysis – Financial Results
- AdAlta Limited (1AD.AX) Income Statement Analysis – Financial Results
- PT MNC Vision Networks Tbk (IPTV.JK) Income Statement Analysis – Financial Results
- Mainland Headwear Holdings Limited (1100.HK) Income Statement Analysis – Financial Results
Embecta Corp. (EMBC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.embecta.com
About Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 1.12B | 1.12B | 1.13B | 1.17B | 1.09B | 1.11B |
| Cost of Revenue | 387.90M | 370.90M | 354.60M | 365.00M | 322.90M | 323.00M |
| Gross Profit | 735.20M | 749.90M | 774.90M | 800.00M | 762.60M | 786.00M |
| Gross Profit Ratio | 65.46% | 66.91% | 68.61% | 68.67% | 70.25% | 70.87% |
| Research & Development | 78.80M | 85.20M | 66.90M | 63.00M | 61.40M | 62.00M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | -300.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 240.00M | 215.00M | 222.00M |
| SG&A | 365.10M | 341.30M | 294.80M | 240.00M | 214.70M | 222.00M |
| Other Expenses | 124.50M | 101.90M | 44.70M | 5.00M | -700.00K | -2.00M |
| Operating Expenses | 568.40M | 528.40M | 406.40M | 308.00M | 276.10M | 284.00M |
| Cost & Expenses | 956.30M | 899.30M | 761.00M | 673.00M | 599.00M | 607.00M |
| Interest Income | 0.00 | 0.00 | 46.20M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 112.30M | 107.00M | 46.20M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 36.20M | 32.60M | 31.70M | 38.00M | 38.00M | 36.00M |
| EBITDA | 199.00M | 245.40M | 400.20M | 530.00M | 524.00M | 538.00M |
| EBITDA Ratio | 17.72% | 21.90% | 34.83% | 45.49% | 48.28% | 48.51% |
| Operating Income | 166.80M | 221.50M | 309.60M | 492.00M | 486.50M | 502.00M |
| Operating Income Ratio | 14.85% | 19.76% | 27.41% | 42.23% | 44.82% | 45.27% |
| Total Other Income/Expenses | -122.60M | -115.80M | -53.00M | 3.00M | -700.00K | -2.00M |
| Income Before Tax | 44.20M | 105.70M | 256.60M | 495.00M | 485.80M | 500.00M |
| Income Before Tax Ratio | 3.94% | 9.43% | 22.72% | 42.49% | 44.75% | 45.09% |
| Income Tax Expense | -34.10M | 35.30M | 33.00M | 80.00M | 58.20M | 68.00M |
| Net Income | 78.30M | 70.40M | 223.60M | 414.80M | 427.60M | 432.00M |
| Net Income Ratio | 6.97% | 6.28% | 19.80% | 35.61% | 39.39% | 38.95% |
| EPS | 1.36 | 1.23 | 3.92 | 7.31 | 7.50 | 7.58 |
| EPS Diluted | 1.34 | 1.22 | 3.92 | 7.31 | 7.50 | 7.58 |
| Weighted Avg Shares Out | 0.00 | 57.24M | 57.06M | 56.80M | 57.00M | 57.00M |
| Weighted Avg Shares Out (Dil) | 0.00 | 57.76M | 57.06M | 56.80M | 57.00M | 57.00M |
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is...
Embecta: Mammoth Effort Needed To Get Investors Over The Line, Reiterate Hold
Embecta Corp.'s stock has dropped 31% since its last publication, and analysis suggests this trend may continue. Despite securing key partnerships and signing multi-year agreements, projected revenue and earnings growth is flat. Net-net, reiterate hold on Embecta Corp.
embecta to Report Fiscal Third Quarter 2023 Financial Results
PARSIPPANY, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, will host a conference call to discuss its fiscal third quarter 2023 financial results, provide an operational update, and host a question...
UPDATE -- embecta to Participate in Investor Conferences
PARSIPPANY, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following investor conferences:
embecta to Participate in Investor Conferences
PARSIPPANY, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following investor conferences:
Embecta (EMBC) to Report Q2 Earnings: What's in Store?
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
3 Top Dividend Kings to Buy for the Long Haul
Johnson & Johnson just raised its quarterly dividend for the 61st straight year. AbbVie is counting on Skyrizi and Rinvoq and its deep pipeline to help replace lost revenue from Humira.
embecta to Report Fiscal Second Quarter 2023 Financial Results
PARSIPPANY, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal second quarter 2023 financial results, provide an...
DivHut Portfolio Update: March 2023
The system is clearly broken, and has been for a while; however, I could find comfort in one thing, my dividends. Four figures in a month is a win in my book. Earning $1,893.81 represents 12.6% year over year increase...
New Strong Buy Stocks for April 4th
EMBC, BNPQY, OLLI, CASY and JRVR have been added to the Zacks Rank #1 (Strong Buy) List on April 4, 2023.
Source: https://incomestatements.info
Category: Stock Reports